 Robert Page
Concepts (651)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 34 | 2023 | 1969 | 4.500 |
Why?
| | Acute Coronary Syndrome | 8 | 2022 | 257 | 1.930 |
Why?
| | Immunosuppressive Agents | 10 | 2021 | 681 | 1.920 |
Why?
| | American Heart Association | 10 | 2022 | 270 | 1.780 |
Why?
| | Cardiovascular Agents | 7 | 2018 | 126 | 1.740 |
Why?
| | Health Resources | 4 | 2016 | 132 | 1.540 |
Why?
| | Medical Marijuana | 3 | 2021 | 102 | 1.500 |
Why?
| | Atrial Fibrillation | 15 | 2021 | 338 | 1.450 |
Why?
| | Stroke Volume | 8 | 2023 | 513 | 1.300 |
Why?
| | Anti-Arrhythmia Agents | 13 | 2014 | 113 | 1.220 |
Why?
| | Marijuana Smoking | 2 | 2021 | 220 | 1.200 |
Why?
| | Polypharmacy | 5 | 2023 | 75 | 1.190 |
Why?
| | Drug Interactions | 14 | 2021 | 352 | 1.120 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 301 | 1.100 |
Why?
| | Defibrillators, Implantable | 11 | 2001 | 299 | 1.050 |
Why?
| | Electric Countershock | 9 | 2001 | 110 | 1.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2022 | 245 | 0.990 |
Why?
| | Heart Transplantation | 11 | 2017 | 671 | 0.970 |
Why?
| | Cost of Illness | 3 | 2014 | 258 | 0.940 |
Why?
| | Humans | 155 | 2023 | 118974 | 0.930 |
Why?
| | Aminobutyrates | 1 | 2023 | 32 | 0.890 |
Why?
| | Cocaine | 2 | 2019 | 158 | 0.870 |
Why?
| | Theophylline | 1 | 2022 | 60 | 0.860 |
Why?
| | Arrhythmias, Cardiac | 9 | 2001 | 277 | 0.860 |
Why?
| | Health Expenditures | 2 | 2014 | 174 | 0.850 |
Why?
| | Drugs, Generic | 2 | 2020 | 18 | 0.850 |
Why?
| | Organ Transplantation | 2 | 2021 | 165 | 0.800 |
Why?
| | Graft Rejection | 4 | 2020 | 555 | 0.790 |
Why?
| | Propanolamines | 2 | 2019 | 93 | 0.780 |
Why?
| | Health Care Costs | 2 | 2014 | 394 | 0.760 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 387 | 0.750 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 3 | 2017 | 12 | 0.750 |
Why?
| | Drug Hypersensitivity | 5 | 2008 | 83 | 0.740 |
Why?
| | Inpatients | 2 | 2016 | 388 | 0.710 |
Why?
| | Aged | 52 | 2022 | 19657 | 0.700 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2011 | 155 | 0.690 |
Why?
| | Cardiovascular System | 1 | 2020 | 127 | 0.670 |
Why?
| | Anti-Infective Agents | 5 | 2010 | 227 | 0.670 |
Why?
| | Consensus | 2 | 2020 | 534 | 0.660 |
Why?
| | Marijuana Abuse | 1 | 2021 | 209 | 0.650 |
Why?
| | Middle Aged | 60 | 2021 | 27617 | 0.640 |
Why?
| | Lung Transplantation | 1 | 2020 | 263 | 0.630 |
Why?
| | Prescription Drugs | 2 | 2016 | 113 | 0.630 |
Why?
| | Hospitalization | 12 | 2023 | 1785 | 0.620 |
Why?
| | Cardiovascular Diseases | 7 | 2021 | 1798 | 0.620 |
Why?
| | Male | 81 | 2021 | 57801 | 0.610 |
Why?
| | Heart Rate | 16 | 2021 | 729 | 0.610 |
Why?
| | Sick Leave | 2 | 2014 | 12 | 0.600 |
Why?
| | Tachycardia, Ventricular | 10 | 2001 | 151 | 0.600 |
Why?
| | Purines | 2 | 2022 | 161 | 0.590 |
Why?
| | Pregnancy Complications, Cardiovascular | 4 | 2001 | 70 | 0.590 |
Why?
| | Drug Monitoring | 5 | 2016 | 187 | 0.580 |
Why?
| | Anticoagulants | 8 | 2021 | 559 | 0.580 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2174 | 0.580 |
Why?
| | Chronic Disease | 8 | 2020 | 1636 | 0.570 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 32 | 0.550 |
Why?
| | Female | 74 | 2021 | 61565 | 0.550 |
Why?
| | Ranolazine | 1 | 2015 | 21 | 0.540 |
Why?
| | Public Health | 1 | 2020 | 450 | 0.540 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2016 | 84 | 0.540 |
Why?
| | Survival | 1 | 2015 | 39 | 0.530 |
Why?
| | Renin-Angiotensin System | 1 | 2016 | 82 | 0.530 |
Why?
| | Angina, Stable | 1 | 2015 | 17 | 0.530 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 38 | 0.530 |
Why?
| | Calcium Channel Blockers | 2 | 2015 | 117 | 0.530 |
Why?
| | United States | 22 | 2022 | 12555 | 0.520 |
Why?
| | Treatment Outcome | 15 | 2023 | 9342 | 0.520 |
Why?
| | Physical Therapy Specialty | 2 | 2006 | 33 | 0.520 |
Why?
| | Hospital Costs | 1 | 2016 | 110 | 0.520 |
Why?
| | Employer Health Costs | 1 | 2014 | 4 | 0.510 |
Why?
| | Pyrazoles | 2 | 2022 | 363 | 0.510 |
Why?
| | Cardiac Pacing, Artificial | 9 | 2001 | 85 | 0.510 |
Why?
| | Patient Discharge | 6 | 2021 | 796 | 0.500 |
Why?
| | Patient Admission | 1 | 2016 | 176 | 0.490 |
Why?
| | Practice Guidelines as Topic | 4 | 2018 | 1440 | 0.480 |
Why?
| | Electrocardiography | 18 | 2013 | 556 | 0.480 |
Why?
| | Vasodilator Agents | 5 | 2016 | 328 | 0.480 |
Why?
| | Drug Utilization Review | 2 | 2006 | 60 | 0.480 |
Why?
| | Adult | 42 | 2020 | 31512 | 0.480 |
Why?
| | Tacrolimus | 4 | 2016 | 151 | 0.480 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 195 | 0.470 |
Why?
| | Catheter Ablation | 6 | 2000 | 286 | 0.470 |
Why?
| | Muscular Diseases | 2 | 2019 | 107 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1200 | 0.460 |
Why?
| | Mortality | 1 | 2015 | 299 | 0.460 |
Why?
| | Hospital Mortality | 2 | 2016 | 814 | 0.460 |
Why?
| | Daptomycin | 1 | 2013 | 19 | 0.450 |
Why?
| | Aged, 80 and over | 15 | 2021 | 6561 | 0.450 |
Why?
| | Sulfonamides | 5 | 2013 | 445 | 0.450 |
Why?
| | Creatine Kinase | 1 | 2013 | 75 | 0.450 |
Why?
| | Drug Prescriptions | 3 | 2010 | 248 | 0.440 |
Why?
| | Retrospective Studies | 18 | 2021 | 12978 | 0.430 |
Why?
| | Platelet Aggregation Inhibitors | 4 | 2018 | 402 | 0.430 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 126 | 0.430 |
Why?
| | Pharmaceutical Services | 1 | 2013 | 79 | 0.430 |
Why?
| | Baroreflex | 5 | 2021 | 53 | 0.420 |
Why?
| | Hiccup | 1 | 2011 | 2 | 0.420 |
Why?
| | Models, Organizational | 1 | 2013 | 146 | 0.420 |
Why?
| | Pharmacy Service, Hospital | 4 | 2015 | 86 | 0.420 |
Why?
| | Cities | 1 | 2012 | 96 | 0.410 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2011 | 23 | 0.410 |
Why?
| | Ventricular Fibrillation | 4 | 2001 | 51 | 0.410 |
Why?
| | Medicaid | 1 | 2015 | 411 | 0.410 |
Why?
| | Amines | 1 | 2011 | 41 | 0.410 |
Why?
| | Drug Overdose | 1 | 2015 | 294 | 0.400 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2018 | 1185 | 0.400 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 5 | 2000 | 27 | 0.400 |
Why?
| | Atrioventricular Node | 4 | 1997 | 13 | 0.390 |
Why?
| | Medication Errors | 3 | 2013 | 92 | 0.390 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 234 | 0.390 |
Why?
| | Patient Education as Topic | 3 | 2013 | 699 | 0.380 |
Why?
| | Drug Substitution | 3 | 2020 | 46 | 0.380 |
Why?
| | Myocardial Infarction | 3 | 2013 | 968 | 0.380 |
Why?
| | Adenosine | 3 | 2018 | 211 | 0.370 |
Why?
| | Seizures | 2 | 2012 | 345 | 0.370 |
Why?
| | Heart Conduction System | 9 | 2001 | 81 | 0.370 |
Why?
| | Transplant Recipients | 3 | 2017 | 148 | 0.370 |
Why?
| | Central Nervous System Agents | 1 | 2009 | 6 | 0.360 |
Why?
| | Electrocardiography, Ambulatory | 6 | 1999 | 53 | 0.360 |
Why?
| | Aircraft | 3 | 2001 | 28 | 0.360 |
Why?
| | Health Services Accessibility | 1 | 2016 | 781 | 0.350 |
Why?
| | Clinical Protocols | 3 | 2017 | 238 | 0.350 |
Why?
| | Desensitization, Immunologic | 2 | 2008 | 113 | 0.340 |
Why?
| | Tobacco Smoke Pollution | 1 | 2012 | 233 | 0.340 |
Why?
| | Central Nervous System Diseases | 1 | 2009 | 64 | 0.340 |
Why?
| | Risk Factors | 11 | 2022 | 9000 | 0.340 |
Why?
| | Electrodes, Implanted | 4 | 1997 | 97 | 0.340 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 417 | 0.330 |
Why?
| | Premature Birth | 1 | 2012 | 284 | 0.320 |
Why?
| | Drug Costs | 2 | 2013 | 94 | 0.320 |
Why?
| | Cost Sharing | 1 | 2008 | 14 | 0.320 |
Why?
| | Restless Legs Syndrome | 1 | 2008 | 19 | 0.320 |
Why?
| | Citalopram | 1 | 2008 | 27 | 0.320 |
Why?
| | Pain | 2 | 2006 | 735 | 0.320 |
Why?
| | Helicobacter Infections | 1 | 2007 | 25 | 0.310 |
Why?
| | Helicobacter pylori | 1 | 2007 | 31 | 0.310 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2017 | 1945 | 0.310 |
Why?
| | Pacemaker, Artificial | 3 | 2001 | 105 | 0.310 |
Why?
| | Ticlopidine | 1 | 2008 | 61 | 0.310 |
Why?
| | Cyclosporine | 3 | 2010 | 173 | 0.300 |
Why?
| | Cardiology | 3 | 2023 | 272 | 0.300 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.300 |
Why?
| | Exanthema | 1 | 2008 | 77 | 0.300 |
Why?
| | Tachycardia, Supraventricular | 6 | 2001 | 40 | 0.300 |
Why?
| | Prasugrel Hydrochloride | 2 | 2018 | 18 | 0.300 |
Why?
| | Telemedicine | 1 | 2015 | 664 | 0.290 |
Why?
| | Managed Care Programs | 1 | 2008 | 135 | 0.290 |
Why?
| | Analgesics | 1 | 2008 | 159 | 0.290 |
Why?
| | Imidazolidines | 3 | 2001 | 19 | 0.290 |
Why?
| | Epistaxis | 1 | 2006 | 11 | 0.290 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2006 | 69 | 0.280 |
Why?
| | Warfarin | 4 | 2021 | 139 | 0.280 |
Why?
| | Health Behavior | 1 | 2012 | 720 | 0.280 |
Why?
| | Comorbidity | 6 | 2016 | 1527 | 0.280 |
Why?
| | Salvage Therapy | 1 | 2007 | 130 | 0.280 |
Why?
| | Sympathetic Nervous System | 5 | 2001 | 171 | 0.270 |
Why?
| | Triazoles | 1 | 2007 | 134 | 0.270 |
Why?
| | Pharmacists | 3 | 2015 | 238 | 0.270 |
Why?
| | Diabetic Neuropathies | 1 | 2006 | 78 | 0.270 |
Why?
| | Imidazoles | 3 | 2001 | 232 | 0.260 |
Why?
| | Metronidazole | 1 | 2005 | 21 | 0.260 |
Why?
| | Models, Economic | 2 | 2016 | 48 | 0.260 |
Why?
| | Colorado | 8 | 2015 | 4196 | 0.260 |
Why?
| | Medication Adherence | 5 | 2018 | 556 | 0.250 |
Why?
| | Thrombosis | 2 | 2021 | 309 | 0.250 |
Why?
| | Fructose | 1 | 2006 | 204 | 0.250 |
Why?
| | Coronary Disease | 2 | 1998 | 356 | 0.250 |
Why?
| | Risk Assessment | 7 | 2022 | 3057 | 0.250 |
Why?
| | Smoking | 1 | 2012 | 1487 | 0.250 |
Why?
| | Length of Stay | 3 | 2016 | 1032 | 0.240 |
Why?
| | Piperazines | 3 | 2001 | 316 | 0.240 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2005 | 116 | 0.240 |
Why?
| | Salaries and Fringe Benefits | 2 | 2014 | 54 | 0.240 |
Why?
| | Young Adult | 7 | 2016 | 10793 | 0.230 |
Why?
| | Metoprolol | 3 | 2001 | 37 | 0.230 |
Why?
| | Research Design | 1 | 2009 | 969 | 0.230 |
Why?
| | Vagus Nerve | 2 | 1996 | 80 | 0.230 |
Why?
| | Cardiac Catheterization | 4 | 2008 | 541 | 0.230 |
Why?
| | Valsartan | 1 | 2023 | 22 | 0.230 |
Why?
| | Dietary Supplements | 2 | 2010 | 467 | 0.230 |
Why?
| | Adolescent | 10 | 2016 | 18480 | 0.220 |
Why?
| | Biphenyl Compounds | 1 | 2023 | 52 | 0.220 |
Why?
| | Pressoreceptors | 2 | 2021 | 18 | 0.220 |
Why?
| | Aminophylline | 1 | 2022 | 5 | 0.220 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 468 | 0.220 |
Why?
| | Sodium | 1 | 2023 | 200 | 0.210 |
Why?
| | Thiazolidinediones | 1 | 2003 | 146 | 0.210 |
Why?
| | Nitroprusside | 3 | 2016 | 88 | 0.210 |
Why?
| | Drug Therapy, Combination | 6 | 2016 | 965 | 0.210 |
Why?
| | Fluorobenzenes | 2 | 2013 | 13 | 0.210 |
Why?
| | Time Factors | 9 | 2016 | 6412 | 0.210 |
Why?
| | Heart-Assist Devices | 2 | 2021 | 485 | 0.210 |
Why?
| | Drug Combinations | 1 | 2023 | 291 | 0.210 |
Why?
| | Pharmacogenomic Testing | 2 | 2020 | 54 | 0.210 |
Why?
| | Education, Pharmacy | 3 | 2016 | 130 | 0.210 |
Why?
| | Troponin I | 2 | 2000 | 83 | 0.210 |
Why?
| | Prognosis | 6 | 2022 | 3443 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1244 | 0.210 |
Why?
| | Anti-Bacterial Agents | 3 | 2013 | 1510 | 0.200 |
Why?
| | Azithromycin | 1 | 2001 | 81 | 0.200 |
Why?
| | Students, Pharmacy | 2 | 2016 | 99 | 0.200 |
Why?
| | Equipment Failure | 6 | 2001 | 114 | 0.190 |
Why?
| | Hyperthermia, Induced | 7 | 2000 | 67 | 0.190 |
Why?
| | Clinical Decision-Making | 2 | 2021 | 278 | 0.190 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 992 | 0.190 |
Why?
| | Policy Making | 1 | 2021 | 86 | 0.190 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 516 | 0.190 |
Why?
| | Tachycardia, Paroxysmal | 3 | 1995 | 7 | 0.180 |
Why?
| | Equipment Design | 6 | 2001 | 519 | 0.180 |
Why?
| | Heart Arrest | 3 | 2001 | 291 | 0.180 |
Why?
| | Reflex, Abnormal | 1 | 1999 | 8 | 0.180 |
Why?
| | Health Services Needs and Demand | 2 | 2016 | 254 | 0.180 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 122 | 0.180 |
Why?
| | Prospective Studies | 8 | 2020 | 6471 | 0.180 |
Why?
| | Drugs, Chinese Herbal | 1 | 1999 | 14 | 0.180 |
Why?
| | Health Personnel | 1 | 2005 | 588 | 0.180 |
Why?
| | Geriatric Assessment | 2 | 2019 | 185 | 0.170 |
Why?
| | Cannabinoids | 1 | 2021 | 115 | 0.170 |
Why?
| | Canada | 1 | 2020 | 340 | 0.170 |
Why?
| | Blood Pressure | 6 | 2021 | 1664 | 0.170 |
Why?
| | Coated Materials, Biocompatible | 1 | 1999 | 58 | 0.170 |
Why?
| | Pyrimidines | 2 | 2013 | 382 | 0.170 |
Why?
| | Cardiologists | 1 | 2018 | 40 | 0.170 |
Why?
| | Heart Injuries | 1 | 1999 | 38 | 0.160 |
Why?
| | Glucose | 2 | 2023 | 953 | 0.160 |
Why?
| | Benzazepines | 1 | 2018 | 38 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 5 | 2020 | 374 | 0.160 |
Why?
| | Monitoring, Ambulatory | 1 | 1999 | 84 | 0.160 |
Why?
| | Heart Septal Defects, Atrial | 1 | 1998 | 50 | 0.160 |
Why?
| | Triazines | 1 | 1998 | 39 | 0.160 |
Why?
| | Stevens-Johnson Syndrome | 1 | 1998 | 34 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 62 | 0.160 |
Why?
| | Dexamethasone | 1 | 1999 | 320 | 0.150 |
Why?
| | Food, Fortified | 1 | 1997 | 37 | 0.150 |
Why?
| | Diuretics | 1 | 2017 | 76 | 0.150 |
Why?
| | Nutritional Physiological Phenomena | 1 | 1997 | 54 | 0.150 |
Why?
| | Patient Participation | 1 | 2020 | 369 | 0.150 |
Why?
| | Clinical Competence | 4 | 2012 | 951 | 0.140 |
Why?
| | Hypoglycemic Agents | 2 | 2005 | 1032 | 0.140 |
Why?
| | Administration, Oral | 5 | 2021 | 756 | 0.140 |
Why?
| | Mexiletine | 1 | 2016 | 7 | 0.140 |
Why?
| | Thiocyanates | 1 | 2016 | 29 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2022 | 496 | 0.140 |
Why?
| | Amphetamine | 1 | 2016 | 23 | 0.140 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2016 | 46 | 0.140 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2006 | 37 | 0.140 |
Why?
| | Medication Reconciliation | 2 | 2013 | 25 | 0.140 |
Why?
| | Tetralogy of Fallot | 1 | 1997 | 79 | 0.140 |
Why?
| | HIV | 1 | 2017 | 210 | 0.140 |
Why?
| | Ventricular Function | 1 | 1996 | 60 | 0.140 |
Why?
| | Neural Tube Defects | 1 | 1997 | 63 | 0.140 |
Why?
| | Intensive Care Units | 3 | 2019 | 635 | 0.140 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 60 | 0.140 |
Why?
| | Anticonvulsants | 1 | 1998 | 184 | 0.140 |
Why?
| | Sex Factors | 3 | 2015 | 1781 | 0.140 |
Why?
| | Amiodarone | 3 | 2001 | 24 | 0.140 |
Why?
| | Rosuvastatin Calcium | 2 | 2013 | 19 | 0.140 |
Why?
| | Folic Acid | 1 | 1997 | 161 | 0.140 |
Why?
| | Substance Abuse Detection | 1 | 2016 | 63 | 0.140 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 67 | 0.140 |
Why?
| | Nitroglycerin | 1 | 2015 | 24 | 0.130 |
Why?
| | Patient Safety | 2 | 2016 | 281 | 0.130 |
Why?
| | Follow-Up Studies | 7 | 2015 | 4596 | 0.130 |
Why?
| | Patient Readmission | 3 | 2021 | 634 | 0.130 |
Why?
| | Anti-Retroviral Agents | 1 | 2017 | 208 | 0.130 |
Why?
| | Societies, Pharmaceutical | 2 | 2013 | 28 | 0.130 |
Why?
| | Certification | 2 | 2006 | 99 | 0.130 |
Why?
| | Pre-Excitation Syndromes | 1 | 1995 | 5 | 0.130 |
Why?
| | Prevalence | 3 | 2023 | 2326 | 0.130 |
Why?
| | Insurance, Disability | 1 | 2014 | 1 | 0.130 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 554 | 0.130 |
Why?
| | Age Distribution | 1 | 2015 | 362 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2016 | 162 | 0.130 |
Why?
| | Exercise Test | 2 | 2021 | 551 | 0.130 |
Why?
| | Antidotes | 1 | 2016 | 126 | 0.130 |
Why?
| | Quality Improvement | 3 | 2020 | 963 | 0.130 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 52 | 0.130 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 215 | 0.130 |
Why?
| | Absenteeism | 1 | 2014 | 38 | 0.130 |
Why?
| | Comparative Effectiveness Research | 1 | 2015 | 132 | 0.130 |
Why?
| | Health Services | 1 | 2015 | 110 | 0.130 |
Why?
| | Soft Tissue Neoplasms | 4 | 2000 | 93 | 0.120 |
Why?
| | Hemorrhage | 4 | 2021 | 623 | 0.120 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2005 | 344 | 0.120 |
Why?
| | Life Style | 2 | 2018 | 430 | 0.120 |
Why?
| | Insurance Claim Review | 1 | 2014 | 67 | 0.120 |
Why?
| | Efficiency | 1 | 2014 | 89 | 0.120 |
Why?
| | Risk | 2 | 2017 | 853 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2014 | 202 | 0.120 |
Why?
| | Mass Casualty Incidents | 1 | 2014 | 38 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 4708 | 0.120 |
Why?
| | Torsades de Pointes | 1 | 2013 | 17 | 0.120 |
Why?
| | Homicide | 1 | 2014 | 53 | 0.120 |
Why?
| | Databases, Factual | 2 | 2018 | 1231 | 0.120 |
Why?
| | Blood Pressure Determination | 1 | 2014 | 133 | 0.120 |
Why?
| | Procainamide | 1 | 1993 | 5 | 0.110 |
Why?
| | Linear Models | 1 | 2016 | 827 | 0.110 |
Why?
| | Medicare | 2 | 2015 | 663 | 0.110 |
Why?
| | Blood Coagulation | 1 | 2014 | 219 | 0.110 |
Why?
| | Pregnancy | 5 | 2012 | 5691 | 0.110 |
Why?
| | Calcineurin Inhibitors | 2 | 2010 | 61 | 0.110 |
Why?
| | Long QT Syndrome | 1 | 2013 | 57 | 0.110 |
Why?
| | Medical Staff | 1 | 2012 | 16 | 0.110 |
Why?
| | Simvastatin | 1 | 2013 | 65 | 0.110 |
Why?
| | Dog Diseases | 4 | 1999 | 44 | 0.110 |
Why?
| | Adenosine A2 Receptor Antagonists | 1 | 2012 | 11 | 0.110 |
Why?
| | Regression Analysis | 5 | 2016 | 983 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1474 | 0.110 |
Why?
| | Critical Care | 2 | 2016 | 492 | 0.110 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 124 | 0.110 |
Why?
| | Chronic Pain | 1 | 2015 | 211 | 0.110 |
Why?
| | Postoperative Complications | 2 | 2005 | 2235 | 0.110 |
Why?
| | Hemodynamics | 4 | 2021 | 1004 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 794 | 0.100 |
Why?
| | Phenylephrine | 3 | 1999 | 85 | 0.100 |
Why?
| | Models, Educational | 1 | 2012 | 99 | 0.100 |
Why?
| | Maternal Age | 1 | 2012 | 122 | 0.100 |
Why?
| | Bisoprolol | 1 | 2011 | 5 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2015 | 3171 | 0.100 |
Why?
| | Foundations | 1 | 2011 | 22 | 0.100 |
Why?
| | Residence Characteristics | 2 | 2012 | 299 | 0.100 |
Why?
| | Health Policy | 2 | 2011 | 333 | 0.100 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 73 | 0.100 |
Why?
| | Health Services Misuse | 2 | 2020 | 36 | 0.100 |
Why?
| | Wounds, Gunshot | 1 | 2014 | 176 | 0.100 |
Why?
| | Sinoatrial Node | 1 | 1991 | 32 | 0.100 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 38 | 0.100 |
Why?
| | Carbazoles | 1 | 2011 | 80 | 0.100 |
Why?
| | Research Report | 1 | 2011 | 75 | 0.100 |
Why?
| | Drug Information Services | 2 | 2013 | 9 | 0.100 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 525 | 0.100 |
Why?
| | Contraindications | 2 | 2002 | 86 | 0.100 |
Why?
| | Piperidines | 1 | 1992 | 171 | 0.100 |
Why?
| | Acute Disease | 2 | 2018 | 940 | 0.090 |
Why?
| | Primary Prevention | 2 | 2010 | 185 | 0.090 |
Why?
| | Heart Atria | 3 | 2000 | 112 | 0.090 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 455 | 0.090 |
Why?
| | DNA | 1 | 2016 | 1388 | 0.090 |
Why?
| | Complementary Therapies | 1 | 2010 | 71 | 0.090 |
Why?
| | Delphi Technique | 1 | 2009 | 164 | 0.090 |
Why?
| | Depressive Disorder | 1 | 2012 | 333 | 0.090 |
Why?
| | Quality Assurance, Health Care | 2 | 2013 | 325 | 0.080 |
Why?
| | Pregabalin | 1 | 2008 | 10 | 0.080 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 2008 | 15 | 0.080 |
Why?
| | Monoamine Oxidase | 1 | 2008 | 25 | 0.080 |
Why?
| | Antiparkinson Agents | 1 | 2008 | 26 | 0.080 |
Why?
| | Biological Products | 1 | 2011 | 170 | 0.080 |
Why?
| | Cohort Studies | 2 | 2016 | 5116 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2010 | 360 | 0.080 |
Why?
| | Pharmacogenetics | 2 | 2020 | 151 | 0.080 |
Why?
| | Patient Care Team | 1 | 2013 | 521 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 589 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2062 | 0.080 |
Why?
| | Cardiomyopathies | 3 | 2017 | 299 | 0.080 |
Why?
| | Analgesics, Opioid | 1 | 2015 | 794 | 0.080 |
Why?
| | Omeprazole | 1 | 2007 | 5 | 0.080 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2008 | 21 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 589 | 0.080 |
Why?
| | Benchmarking | 2 | 2023 | 172 | 0.080 |
Why?
| | Age Factors | 3 | 2009 | 2995 | 0.080 |
Why?
| | Amoxicillin | 1 | 2007 | 20 | 0.080 |
Why?
| | Levofloxacin | 1 | 2007 | 22 | 0.080 |
Why?
| | Ofloxacin | 1 | 2007 | 23 | 0.080 |
Why?
| | Professional Role | 2 | 2006 | 153 | 0.080 |
Why?
| | Conflict of Interest | 1 | 2009 | 120 | 0.080 |
Why?
| | Cardiotonic Agents | 2 | 1999 | 127 | 0.080 |
Why?
| | Peer Review, Research | 1 | 2008 | 35 | 0.080 |
Why?
| | Substance-Related Disorders | 1 | 2016 | 971 | 0.080 |
Why?
| | Drug-Eluting Stents | 1 | 2008 | 66 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2010 | 241 | 0.080 |
Why?
| | Atrial Function | 2 | 1999 | 11 | 0.080 |
Why?
| | Societies, Medical | 1 | 2011 | 703 | 0.080 |
Why?
| | Injections, Intravenous | 2 | 2001 | 210 | 0.080 |
Why?
| | Mucor | 1 | 2007 | 7 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2017 | 4552 | 0.080 |
Why?
| | Atrial Flutter | 3 | 2000 | 24 | 0.070 |
Why?
| | Hydantoins | 3 | 2001 | 5 | 0.070 |
Why?
| | Hydrochlorothiazide | 1 | 2006 | 11 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 87 | 0.070 |
Why?
| | Hypertension | 2 | 2014 | 1203 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 46 | 0.070 |
Why?
| | Neuralgia | 1 | 2008 | 120 | 0.070 |
Why?
| | Angioedema | 1 | 2006 | 17 | 0.070 |
Why?
| | Proton Pump Inhibitors | 1 | 2007 | 98 | 0.070 |
Why?
| | Registries | 1 | 2014 | 1810 | 0.070 |
Why?
| | Metabolic Clearance Rate | 2 | 2005 | 113 | 0.070 |
Why?
| | Antidepressive Agents | 2 | 2005 | 189 | 0.070 |
Why?
| | Disease Management | 2 | 2021 | 571 | 0.070 |
Why?
| | Clinical Trials as Topic | 4 | 2010 | 969 | 0.070 |
Why?
| | Alcohol Drinking | 1 | 2012 | 652 | 0.070 |
Why?
| | Professional Autonomy | 1 | 2006 | 25 | 0.070 |
Why?
| | Antihypertensive Agents | 2 | 2006 | 437 | 0.070 |
Why?
| | Preceptorship | 1 | 2006 | 63 | 0.070 |
Why?
| | Education, Continuing | 1 | 2006 | 40 | 0.070 |
Why?
| | Drug Utilization | 1 | 2006 | 169 | 0.070 |
Why?
| | Hospitals, University | 1 | 2006 | 172 | 0.070 |
Why?
| | Pharmaceutical Preparations | 1 | 2008 | 167 | 0.070 |
Why?
| | Medical History Taking | 1 | 2006 | 120 | 0.070 |
Why?
| | Combined Modality Therapy | 5 | 2000 | 1166 | 0.070 |
Why?
| | Norepinephrine | 3 | 2021 | 212 | 0.070 |
Why?
| | Curriculum | 2 | 2016 | 910 | 0.070 |
Why?
| | Disease-Free Survival | 1 | 2007 | 649 | 0.060 |
Why?
| | Biotransformation | 1 | 2005 | 52 | 0.060 |
Why?
| | Pancreatitis | 1 | 2005 | 108 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 111 | 0.060 |
Why?
| | Incidence | 3 | 2023 | 2424 | 0.060 |
Why?
| | Parkinson Disease | 1 | 2008 | 334 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2000 | 482 | 0.060 |
Why?
| | Odds Ratio | 1 | 2006 | 996 | 0.060 |
Why?
| | Biological Transport | 1 | 2005 | 382 | 0.060 |
Why?
| | Educational Measurement | 1 | 2006 | 289 | 0.060 |
Why?
| | Reflex | 2 | 1996 | 64 | 0.060 |
Why?
| | Educational Status | 1 | 2006 | 437 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2006 | 599 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1137 | 0.060 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 415 | 0.060 |
Why?
| | Peroneal Nerve | 2 | 2001 | 19 | 0.060 |
Why?
| | Creatinine | 1 | 2005 | 491 | 0.060 |
Why?
| | Decision Making | 2 | 2019 | 809 | 0.060 |
Why?
| | HIV Infections | 1 | 2017 | 2459 | 0.060 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 380 | 0.060 |
Why?
| | Dogs | 8 | 2000 | 371 | 0.060 |
Why?
| | Mass Screening | 1 | 2010 | 1052 | 0.060 |
Why?
| | Myocardial Ischemia | 2 | 2001 | 251 | 0.060 |
Why?
| | Health Status | 1 | 2008 | 726 | 0.050 |
Why?
| | Paget Disease, Extramammary | 1 | 2002 | 3 | 0.050 |
Why?
| | Recurrence | 3 | 2001 | 975 | 0.050 |
Why?
| | Facial Neoplasms | 1 | 2002 | 18 | 0.050 |
Why?
| | Depression | 2 | 2008 | 1132 | 0.050 |
Why?
| | Sarcoma | 2 | 1994 | 137 | 0.050 |
Why?
| | Patient Selection | 1 | 2006 | 676 | 0.050 |
Why?
| | Drug Therapy | 1 | 2002 | 76 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 647 | 0.050 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 693 | 0.050 |
Why?
| | Electrophysiology | 3 | 2000 | 204 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 12 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 296 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2001 | 30 | 0.050 |
Why?
| | Axilla | 1 | 2001 | 57 | 0.050 |
Why?
| | Sodium Channel Blockers | 1 | 2001 | 24 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2006 | 648 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2012 | 5255 | 0.050 |
Why?
| | Qualitative Research | 1 | 2006 | 953 | 0.050 |
Why?
| | Action Potentials | 3 | 2000 | 420 | 0.050 |
Why?
| | Volunteers | 1 | 2000 | 30 | 0.050 |
Why?
| | Bundle of His | 1 | 2000 | 16 | 0.050 |
Why?
| | Retreatment | 1 | 2000 | 71 | 0.050 |
Why?
| | Parasympathectomy | 1 | 2000 | 1 | 0.050 |
Why?
| | Bundle-Branch Block | 1 | 2000 | 27 | 0.050 |
Why?
| | Shoulder | 1 | 2001 | 94 | 0.050 |
Why?
| | United States Food and Drug Administration | 2 | 2001 | 175 | 0.050 |
Why?
| | Survival Rate | 2 | 2004 | 1720 | 0.050 |
Why?
| | Sarcoma, Experimental | 1 | 2000 | 5 | 0.050 |
Why?
| | Weight Loss | 1 | 2005 | 655 | 0.050 |
Why?
| | Thromboembolism | 1 | 2021 | 99 | 0.050 |
Why?
| | Tilt-Table Test | 1 | 1999 | 7 | 0.050 |
Why?
| | Multimorbidity | 1 | 2019 | 29 | 0.040 |
Why?
| | Maximum Allowable Concentration | 1 | 1999 | 14 | 0.040 |
Why?
| | Angelica sinensis | 1 | 1999 | 2 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1171 | 0.040 |
Why?
| | Prothrombin Time | 1 | 1999 | 35 | 0.040 |
Why?
| | International Normalized Ratio | 1 | 1999 | 45 | 0.040 |
Why?
| | Cisplatin | 2 | 1993 | 271 | 0.040 |
Why?
| | Thoracotomy | 2 | 1997 | 84 | 0.040 |
Why?
| | Electromagnetic Fields | 1 | 1999 | 21 | 0.040 |
Why?
| | Transitional Care | 1 | 2019 | 38 | 0.040 |
Why?
| | Data Display | 1 | 1999 | 22 | 0.040 |
Why?
| | Abnormalities, Drug-Induced | 1 | 1999 | 10 | 0.040 |
Why?
| | Telephone | 3 | 1995 | 152 | 0.040 |
Why?
| | Intraoperative Period | 1 | 1999 | 55 | 0.040 |
Why?
| | Rhabdomyolysis | 1 | 2019 | 18 | 0.040 |
Why?
| | Delirium | 1 | 2019 | 70 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2000 | 227 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2005 | 585 | 0.040 |
Why?
| | Echocardiography | 2 | 1998 | 556 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2000 | 1384 | 0.040 |
Why?
| | Drug Synergism | 1 | 1999 | 339 | 0.040 |
Why?
| | Heart Diseases | 2 | 2005 | 341 | 0.040 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 20 | 0.040 |
Why?
| | Child | 3 | 2015 | 19129 | 0.040 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 100 | 0.040 |
Why?
| | Hydrogen | 1 | 1998 | 65 | 0.040 |
Why?
| | Heart Ventricles | 2 | 2000 | 727 | 0.040 |
Why?
| | Resuscitation | 1 | 2000 | 253 | 0.040 |
Why?
| | Heart Block | 1 | 1997 | 37 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 1 | 1999 | 157 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2000 | 228 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2016 | 2874 | 0.040 |
Why?
| | Digoxin | 1 | 1997 | 27 | 0.040 |
Why?
| | Signal Transduction | 1 | 2010 | 4709 | 0.040 |
Why?
| | Bread | 1 | 1997 | 4 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 1994 | 508 | 0.040 |
Why?
| | Frailty | 1 | 2019 | 116 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1998 | 287 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 1994 | 182 | 0.040 |
Why?
| | Edible Grain | 1 | 1997 | 43 | 0.040 |
Why?
| | Body Surface Area | 1 | 1997 | 28 | 0.040 |
Why?
| | Anesthetics | 1 | 2017 | 58 | 0.040 |
Why?
| | Energy Intake | 1 | 2019 | 447 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 1997 | 75 | 0.040 |
Why?
| | Propensity Score | 1 | 2018 | 242 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 1998 | 656 | 0.040 |
Why?
| | Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 5 | 0.040 |
Why?
| | Chromatography, Gas | 1 | 2016 | 31 | 0.040 |
Why?
| | Electric Conductivity | 1 | 1996 | 91 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1997 | 268 | 0.030 |
Why?
| | Perioperative Care | 1 | 2017 | 132 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 490 | 0.030 |
Why?
| | Surface Properties | 1 | 1997 | 397 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 403 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1996 | 132 | 0.030 |
Why?
| | Diabetes Mellitus | 2 | 2019 | 942 | 0.030 |
Why?
| | Forecasting | 1 | 1997 | 353 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 25 | 0.030 |
Why?
| | Precision Medicine | 1 | 2018 | 363 | 0.030 |
Why?
| | Preoperative Care | 1 | 2017 | 332 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 2016 | 142 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 557 | 0.030 |
Why?
| | PubMed | 1 | 2013 | 12 | 0.030 |
Why?
| | Stochastic Processes | 1 | 1994 | 66 | 0.030 |
Why?
| | Medical Assistance | 1 | 2013 | 15 | 0.030 |
Why?
| | Animals | 10 | 2010 | 33381 | 0.030 |
Why?
| | Acecainide | 1 | 1993 | 1 | 0.030 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2013 | 21 | 0.030 |
Why?
| | Disaster Planning | 1 | 2014 | 76 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 230 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1994 | 324 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 1993 | 69 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 1995 | 251 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2013 | 79 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 499 | 0.030 |
Why?
| | Program Development | 1 | 2014 | 357 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 392 | 0.030 |
Why?
| | Medication Therapy Management | 1 | 2013 | 72 | 0.030 |
Why?
| | Biological Availability | 1 | 1992 | 126 | 0.030 |
Why?
| | Stroke | 1 | 2021 | 1047 | 0.030 |
Why?
| | Education | 1 | 2012 | 105 | 0.030 |
Why?
| | Program Evaluation | 1 | 2016 | 845 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2011 | 18 | 0.030 |
Why?
| | History, 21st Century | 1 | 2012 | 170 | 0.030 |
Why?
| | Internationality | 1 | 2012 | 152 | 0.030 |
Why?
| | Urinary Retention | 1 | 2011 | 19 | 0.030 |
Why?
| | Self Care | 1 | 2014 | 357 | 0.020 |
Why?
| | Kidney | 1 | 2019 | 1353 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 281 | 0.020 |
Why?
| | Random Allocation | 1 | 1992 | 344 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 1995 | 346 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 1999 | 1022 | 0.020 |
Why?
| | Body Temperature | 1 | 1992 | 215 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1992 | 158 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 662 | 0.020 |
Why?
| | Ovarian Neoplasms | 2 | 1993 | 420 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1882 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1816 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 89 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 523 | 0.020 |
Why?
| | Biomarkers | 2 | 2016 | 3588 | 0.020 |
Why?
| | Reference Values | 1 | 1991 | 774 | 0.020 |
Why?
| | Terminal Care | 1 | 2012 | 187 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2513 | 0.020 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2009 | 32 | 0.020 |
Why?
| | Micronutrients | 1 | 2010 | 79 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 610 | 0.020 |
Why?
| | Journal Impact Factor | 1 | 2009 | 28 | 0.020 |
Why?
| | Heart | 2 | 1995 | 631 | 0.020 |
Why?
| | Food | 1 | 2010 | 162 | 0.020 |
Why?
| | Tricuspid Valve | 1 | 1987 | 23 | 0.020 |
Why?
| | Double-Blind Method | 1 | 1992 | 1687 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2012 | 586 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 872 | 0.020 |
Why?
| | Internship, Nonmedical | 1 | 2006 | 17 | 0.020 |
Why?
| | Cross Reactions | 1 | 2006 | 116 | 0.020 |
Why?
| | Specialty Boards | 1 | 2006 | 39 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2436 | 0.020 |
Why?
| | Schools, Pharmacy | 1 | 2006 | 52 | 0.020 |
Why?
| | Probability | 1 | 2006 | 305 | 0.020 |
Why?
| | Temperature | 3 | 1999 | 622 | 0.020 |
Why?
| | Furosemide | 1 | 2005 | 35 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 1994 | 3174 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2000 | 536 | 0.020 |
Why?
| | Faculty | 1 | 2006 | 135 | 0.020 |
Why?
| | Molecular Structure | 1 | 2006 | 459 | 0.020 |
Why?
| | Antimetabolites | 1 | 2004 | 25 | 0.020 |
Why?
| | Growth Inhibitors | 1 | 2004 | 43 | 0.020 |
Why?
| | Azathioprine | 1 | 2004 | 51 | 0.020 |
Why?
| | Everolimus | 1 | 2004 | 64 | 0.020 |
Why?
| | Diphosphonates | 1 | 2005 | 50 | 0.020 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 79 | 0.020 |
Why?
| | Hypolipidemic Agents | 1 | 2005 | 86 | 0.020 |
Why?
| | Gout | 1 | 2005 | 57 | 0.020 |
Why?
| | Blood Glucose | 1 | 1993 | 1939 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2005 | 128 | 0.010 |
Why?
| | Sirolimus | 1 | 2004 | 195 | 0.010 |
Why?
| | Infection Control | 1 | 2005 | 135 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1865 | 0.010 |
Why?
| | Myocardial Contraction | 2 | 1999 | 339 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1541 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2005 | 218 | 0.010 |
Why?
| | Protein Kinases | 1 | 2004 | 310 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 827 | 0.010 |
Why?
| | Nutritional Status | 1 | 2005 | 300 | 0.010 |
Why?
| | Cheek | 1 | 2002 | 16 | 0.010 |
Why?
| | Mohs Surgery | 1 | 2002 | 25 | 0.010 |
Why?
| | Legislation, Medical | 1 | 2001 | 10 | 0.010 |
Why?
| | Device Approval | 1 | 2001 | 21 | 0.010 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 369 | 0.010 |
Why?
| | Osteoporosis | 1 | 2005 | 229 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 521 | 0.010 |
Why?
| | Partial Pressure | 1 | 2000 | 29 | 0.010 |
Why?
| | Parasympathetic Nervous System | 1 | 2000 | 25 | 0.010 |
Why?
| | Central Venous Pressure | 1 | 1999 | 13 | 0.010 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 1999 | 10 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 309 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 1999 | 245 | 0.010 |
Why?
| | Epinephrine | 1 | 2000 | 167 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 89 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 811 | 0.010 |
Why?
| | Biopsy | 1 | 2002 | 1079 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 327 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1267 | 0.010 |
Why?
| | Cutaneous Fistula | 1 | 1995 | 13 | 0.010 |
Why?
| | Oxygen | 1 | 2000 | 854 | 0.010 |
Why?
| | Foreign Bodies | 1 | 1995 | 98 | 0.010 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 5 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1993 | 23 | 0.010 |
Why?
| | Infusions, Parenteral | 1 | 1993 | 37 | 0.010 |
Why?
| | Half-Life | 1 | 1993 | 147 | 0.010 |
Why?
| | Intracellular Fluid | 1 | 1993 | 26 | 0.010 |
Why?
| | Microelectrodes | 1 | 1993 | 33 | 0.010 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 1993 | 18 | 0.010 |
Why?
| | Extracellular Space | 1 | 1993 | 127 | 0.010 |
Why?
| | Phosphates | 1 | 1994 | 167 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1995 | 272 | 0.010 |
Why?
| | Survivors | 1 | 1996 | 418 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1992 | 59 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1995 | 1125 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1993 | 418 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1994 | 439 | 0.010 |
Why?
| | Hepatitis, Animal | 1 | 1987 | 2 | 0.000 |
Why?
| | Endocardium | 1 | 1987 | 31 | 0.000 |
Why?
| | Injections, Intraperitoneal | 1 | 1987 | 108 | 0.000 |
Why?
| | Tachycardia | 1 | 1987 | 48 | 0.000 |
Why?
| | Peritonitis | 1 | 1987 | 79 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1987 | 180 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1987 | 334 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1987 | 1094 | 0.000 |
Why?
| | Lymph Nodes | 1 | 1987 | 455 | 0.000 |
Why?
| | Pulmonary Fibrosis | 1 | 1987 | 303 | 0.000 |
Why?
| | Child, Preschool | 1 | 1994 | 9491 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1987 | 3730 | 0.000 |
Why?
|
|
Page's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|